Management of Schizophrenia

Treatment Algorithm

The American College of Psychiatry recommends starting with monotherapy of a single antipsychotic as the first line, choosing an agent that works as an antagonist or partial agonist of the dopamine D2 receptor 1
The National Institute of Mental Health suggests selecting one atypical antipsychotic (second generation) as initial therapy, with aripiprazol being a potential first-line choice due to its better metabolic profile, low risk of weight gain, and minimal impact on prolactin levels 2, 1
The treatment guidelines advise against using agents with high anticholinergic properties due to their potential to impair cognitive function 1

If the first antipsychotic fails after adequate dose and duration (at least 4-6 weeks), switch to another atypical antipsychotic as monotherapy, considering long-acting injectable formulations or blood concentration measurements to rule out non-response due to non-adherence 3, 1

Clozapine should be initiated if two adequate trials of non-clozapine antipsychotics have failed and there are no absolute contraindications, with approximately 34% of patients requiring clozapine for treatment-resistant schizophrenia 3, 1
The World Health Organization recommends clozapine as the most effective antipsychotic for treatment-resistant patients, which should always be considered seriously before switching to polypharmacy 3

Polypharmacy should only be considered after the above steps have failed to produce satisfactory results, with the combination of aripiprazol and clozapine being the most evidence-supported combination 4, 3, 1
Augmenting clozapine with aripiprazol can reduce the required dose of clozapine, side effects, and residual symptoms 3

Before starting antipsychotics, measure BMI, waist circumference, blood pressure, HbA1c, glucose, lipids, prolactin, liver function, urea and electrolytes, complete blood count, and EKG 2
Monitor glucose levels 4 weeks after initiation, and BMI, waist circumference, and blood pressure weekly for 6 weeks, with all parameters repeated after 3 months and then annually 2

For metabolic side effects (more common with olanzapine, less with aripiprazol), consider switching to an antipsychotic with a better metabolic profile or adding metformin or a GLP-1 receptor agonist 2
For hyperprolactinemia (rare with aripiprazol), switch to aripiprazol or add aripiprazol at a low dose as an adjunct 2

Approximately 70% of patients require long-term treatment to control symptoms, making long-acting injectable formulations valuable for adherence, according to the American Psychiatric Association 5, 1
At least 20% of individuals do not experience a substantial response to monotherapy, requiring escalation of the treatment algorithm, as stated by the National Institute of Mental Health 1
Early intervention is crucial, with evidence showing that delayed treatment can result in irreversible cognitive decline, as recommended by the World Health Organization 1

Cognitive remediation therapy to improve cognitive function (evidence 1B), as recommended by the American Psychological Association 1
Cognitive-behavioral therapy for psychosis (CBTp) shows positive effects on cognition and symptoms (evidence 1B), according to the National Institute of Mental Health 1
Psychoeducation for patients and families can improve overall function and reduce relapse rates (evidence 1B), as stated by the World Health Organization 1